Athanor Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Athanor Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,637	Closed	-$519K	–	756
2020 Q3	$519K	Buy	+3,637	New	+$451K	0.02%	331

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Athanor Capital's JAZZ Position: Q4 2020 in Review

Athanor Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2020, closing a stake of 3,637 shares — an estimated $519K sold.

Athanor Capital first reported a position in JAZZ in Q3 2020 and held it in 1 quarter. The position peaked at $519K in Q3 2020. 437 funds tracked by Wall St. Rank hold JAZZ as of Q4 2020.

Athanor Capital reported no remaining Jazz Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Athanor Capital sold 3,637 Jazz Pharmaceuticals shares in Q4 2020, an estimated $519K.
Athanor Capital first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Athanor Capital's Jazz Pharmaceuticals position peaked at $519K in Q3 2020.
437 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2020.

Based on Athanor Capital's 13F filing for Q4 2020, filed 16 Feb 2021.